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IMPORTANCE Aortic stenosis (AS) has no approved medical treatment. Identifying etiological
pathways for AS could identify pharmacological targets.
OBJECTIVE To identify novel genetic loci and pathways associated with AS.
DESIGN, SETTING, AND PARTICIPANTS This genome-wide association study used a case-control
design to evaluate 44 703 participants (3469 cases of AS) of self-reported European ancestry
from the Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort (from
January 1, 1996, to December 31, 2015). Replication was performed in 7 other cohorts totaling
256 926 participants (5926 cases of AS), with additional analyses performed in 6942
participants from the Cohorts for Heart and Aging Research in Genomic Epidemiology
(CHARGE) Consortium. Follow-up biomarker analyses with aortic valve calcium (AVC) were
also performed. Data were analyzed from May 1, 2017, to December 5, 2019.
EXPOSURES Genetic variants (615 643 variants) and polyunsaturated fatty acids (ω-6 and ω-3)
measured in blood samples.
MAIN OUTCOMES AND MEASURES Aortic stenosis and aortic valve replacement defined by
electronic health records, surgical records, or echocardiography and the presence of AVC
measured by computed tomography.
RESULTS The mean (SD) age of the 44 703 GERA participants was 69.7 (8.4) years, and
22 019 (49.3%) were men. The rs174547 variant at the FADS1/2 locus was associated with AS
(odds ratio [OR] per C allele, 0.88; 95% CI, 0.83-0.93; P = 3.0 × 10−6), with genome-wide
significance after meta-analysis with 7 replication cohorts totaling 312 118 individuals (9395
cases of AS) (OR, 0.91; 95% CI, 0.88-0.94; P = 2.5 × 10−8). A consistent association with AVC
was also observed (OR, 0.91; 95% CI, 0.83-0.99; P = .03). A higher ratio of arachidonic acid
to linoleic acid was associated with AVC (OR per SD of the natural logarithm, 1.19; 95% CI,
1.09-1.30; P = 6.6 × 10−5). In mendelian randomization, increased FADS1 liver expression and
arachidonic acid were associated with AS (OR per unit of normalized expression, 1.31 [95% CI,
1.17-1.48; P = 7.4 × 10−6]; OR per 5–percentage point increase in arachidonic acid for AVC, 1.23
[95% CI, 1.01-1.49; P = .04]; OR per 5–percentage point increase in arachidonic acid for AS,
1.08 [95% CI, 1.04-1.13; P = 4.1 × 10−4]).
CONCLUSIONS AND RELEVANCE Variation at the FADS1/2 locus was associated with AS and
AVC. Findings from biomarker measurements and mendelian randomization appear to link
ω-6 fatty acid biosynthesis to AS, which may represent a therapeutic target.
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A ortic stenosis (AS) remains the leading cause of clini-cal valve disease in the developed world.1 Contempo-rary treatment is limited to replacement of the aortic
valve, because no approved medical therapy currently exists.
The development of such therapy would expand options for
treating AS but is hindered by a limited understanding of the
causal contributors.
A genome-wide association study (GWAS) conducted in the
Cohorts for Heart and Aging Research in Genomic Epidemiol-
ogy (CHARGE) Consortium demonstrated that the LPA locus
(OMIM 152200), which codes for the apolipoprotein(a) moiety
of lipoprotein(a), is causally associated with incident AS and
prevalent aortic valve calcium (AVC), a subclinical phenotype
that precedes AS.2 This association with AS has been robustly
confirmed in multiple cohorts.3-5 Recent clinical trials have dem-
onstrated that significant reductions in lipoprotein(a) levels are
achievable,6-8 which may represent a novel AS prevention strat-
egy. Two recent GWAS (≤2457 cases of AS) have identified TEX41
and PALMD variants as associated with AS, implicating abnor-
mal cardiac development in disease etiology.9,10
A GWAS with a greater number of cases could have im-
proved statistical power to discover additional genetic loci for
AS and identify novel pathways as pharmacological targets. Ac-
cordingly, we performed a GWAS for AS among 44 703 partici-
pants (3469 cases of AS) from the Genetic Epidemiology Re-
search on Adult Health and Aging (GERA) cohort, one of the
largest collections of AS cases in the world. We validated our
findings in 7 additional cohorts totaling 256 926 participants
(5926 cases of AS) and performed genetic and plasma bio-
marker analyses to describe a novel mechanism underlying AS,
with potential therapeutic implications. An overview of the
study is given in eFigure 1 in the Supplement.
Methods
Genetic Discovery and Replication
In the GERA cohort (NCBI Database of Genotypes and Pheno-
types, phs000788.v2.p3), we performed a GWAS for preva-
lent AS (615 643 variants), adjusting for age, age squared, and
sex, among 44 703 unrelated individuals of self-reported Eu-
ropean ancestry, 55 years or older (eTable 1 in the Supple-
ment). We restricted our analysis to European participants
owing to the small numbers of non-European GERA partici-
pants, because differences in genetic structure between an-
cestries may confound our findings. Aortic stenosis status was
ascertained through electronic health records (January 1, 1996,
to December 31, 2015, inclusive), using the International
Classification of Diseases, 9th Revision, diagnosis code for AS
(ICD-9) (424.1) or a procedure code for aortic valve replace-
ment to designate cases; all other individuals were desig-
nated as controls. Individuals with congenital valvular dis-
ease (ICD-9 codes 746-747) were excluded. Details of this case-
control study are given in eMethods in the Supplement. All
participants have provided written, informed consent, and all
relevant internal review boards approved this study. This study
followed the Strengthening the Reporting of Genetic Associa-
tion Studies (STREGA) reporting guideline.
We later received updated GERA data for 55 192 unre-
lated participants of European-ancestry 55 years and older
(3469 cases of AS). Owing to a small number of participants
who withdrew consent after our initial analysis, the compo-
sition of the cases changed slightly, but the significant change
was the addition of 10 489 controls. We imputed the 1 region
that contained a variant demonstrating a novel, potential
association with AS (P ≤ 1 × 10−6) (eMethods in the Supple-
ment) and reassessed the association of the variant with AS,
first adjusted for age, age squared, and sex, and then further
adjusted for (1) dyslipidemia, hypertension, smoking (ever or
never), and diabetes; (2) the LPA variant rs10455872; or (3) 10
principal components in separate models. In 7 replication co-
horts totaling 256 926 participants (5926 cases of AS) (eTable 2
in the Supplement), we estimated the association of this vari-
ant with AS. To assess the overall association of the variant with
AS, we performed a fixed-effects meta-analysis using esti-
mates from discovery and replication cohorts, weighted by the
inverse of their variance. As a sensitivity analysis, we per-
formed a fixed-effects meta-analysis using estimates from only
the replication cohorts.
In the CHARGE Consortium, we estimated the associa-
tion of the variant with prevalent AVC among 6942 predomi-
nantly European participants (2245 participants with AVC).
Aortic valve calcium was quantified using computed tomog-
raphy and dichotomized into presence (Agatston score >0) or
absence (Agatston score = 0) of AVC (eMethods in the Supple-
ment). We also identified previously reported, genome-wide
significant associations with PhenoScanner11 (retrieved
September 23, 2018) and accessed results for this variant in a
GWAS for coronary artery disease (CARDIoGRAMplusC4D
consortium).12
Associations of Fatty Acid Levels With AS and AVC
To investigate mediation of the lead variant through polyun-
saturated fatty acid biosynthesis, we estimated the associa-
tions of 4 polyunsaturated fatty acids (arachidonic acid, lin-
oleic acid, eicosapentaenoic acid, and α-linolenic acid) and
2 polyunsaturated fatty acid ratios reflecting fatty acid desatu-
ration activity (ratio of arachidonic acid to linoleic acid and
Key Points
Question Can genetic analysis identify additional causes of aortic
stenosis?
Findings In this genome-wide association study of 44 703
participants, each copy of a FADS1/2 (fatty acid desaturase) genetic
variant was associated with a 13% decrease in the odds of aortic
stenosis. Results of a meta-analysis with 7 replication cohorts
showed genome-wide significance, with biomarker and mendelian
randomization analyses implicating elevated ω-6 fatty acid levels
as having a potentially causal association with aortic valve calcium
and aortic stenosis.
Meaning These findings demonstrate that the FADS1/2 locus
and fatty acid biosynthesis are associated with aortic stenosis and
should be examined further for their potential as therapeutic
targets.
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ratio of eicosapentaenoic acid to α-linolenic acid) with AVC in
the Framingham Offspring Study (FOS) cohort (n = 1310 [492
cases of AVC]) and European-ancestry participants in the Multi-
Ethnic Study of Atherosclerosis (MESA) cohort (n = 2415 [387
cases of AVC]) (eMethods in the Supplement), because mea-
surements of fatty acid levels were unavailable in the GERA
cohort. We also assessed whether the association of dietary lin-
oleic acid or α-linolenic acid with incident AS in the Malmö Diet
and Cancer Study cohort and prevalent AVC in the FOS and
MESA cohorts was modified by our lead variant (eMethods in
the Supplement).
Mendelian Randomization of Arachidonic Acid, FADS1
Expression, and FADS2 Expression With AS and AVC
Using mendelian randomization, we estimated the associa-
tion of a plasma arachidonic acid genetic risk score with AS (32
variants [eTable 3 in the Supplement]) and AVC (24 variants
[eTable 4 in the Supplement]). Additional sensitivity analy-
ses were (1) removal of the lead variant and (2) inverse variance-
weighted, penalized weighted median, and Egger extension
methods to assess for robustness of the findings. We also as-
sessed whether elevated FADS1 (OMIM 606148) and FADS2
(OMIM 606149) expression in the liver was causally associ-
ated with prevalent AS (5 variants for FADS1 [eTable 5 in the
Supplement]) and AVC (6 variants for FADS1 [eTable 6 in
the Supplement]) using mendelian randomization. Details
are provided in the eMethods in the Supplement.
Statistical Analyses
Data were analyzed from May 1, 2017, to December 5, 2019.
Genome- and locus-wide genetic associations in the GERA
cohort were computed using PLINK, version 2.0.13 The asso-
ciations of fatty acids with AVC in the MESA and FOS cohorts
were estimated using R, version 3.5.1 (R Project for Statistical
Computing), and SAS, version 9.4 (SAS Institute, Inc), respec-
tively. Meta-analyses of the lead variant and mendelian ran-
domization analyses were performed using R, version 3.5.1.
Two-sided P ≤ 5 × 10−8 was deemed significant in the
GWAS, and 2-sided P ≤ .05 was considered significant in
other analyses.
Results
Association of the FADS1/2 Locus With AS and AVC
The discovery cohort of 44 703 participants consisted of 22 019
men (49.3%) and 22 684 women (50.7%), with a mean (SD) age
of 69.7 (8.4) years. We found no evidence of inflated test
statistics in the GWAS for AS (genomic inflation factor, 1.03
[eFigure 2 in the Supplement]). We confirmed the associa-
tions previously reported for LPA and PALMD variants (eTable 7
in the Supplement). The intronic variant rs174547 at the
FADS1/2 (fatty acid desaturase 1 and 2) locus on chromosome
11 was the only variant that demonstrated a novel association
with AS at P ≤ 1 × 10−6 (Figure 1), with each copy of the minor
(C) allele (frequency, 33%) conferring 13% lower odds of AS
(odds ratio [OR] per minor allele, 0.87; 95% CI, 0.83-0.92;
P = 8.5 × 10−7). After imputation of the locus in the larger
set of GERA participants, the association of rs174547 with AS
was essentially unchanged (OR per minor allele, 0.88; 95% CI,
0.83-0.93; P = 3.0 × 10−6), with variants in high linkage dis-
equilibrium also associated with AS (eFigure 3 in the Supple-
ment). Further adjustment for cardiovascular risk factors, the
LPA variant rs10455872, or population substratification did not
materially change these estimates (eTable 8 in the Supple-
ment). Participants who were homozygous for the minor
allele (6182 of 55 192 [11.2%]) had 26% lower odds of AS (OR,
074; 95% CI, 0.65-0.84; P = 2.8 × 10−6) relative to partici-
pants homozygous for the major allele, adjusted for age, age
squared, and sex.
When we combined this result with findings from 7 rep-
lication cohorts in a meta-analysis totaling 312 118 individu-
Figure 1. P Values for the Association of 615 643 Genetic Variants With Aortic Stenosis
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The red line indicates genome-wide
significance (P  5 × 10−8); the blue
line, suggestive evidence of
association (5 × 10−8<P  1 × 10−6).
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als (9395 cases of AS), the overall association reached genome-
wide significance (OR per minor allele, 0.91; 95% CI, 0.88-
0.94; P = 2.5 × 10−8) (Figure 2), and we observed no
heterogeneity in the estimates (I2 = 0%). When only the rep-
lication cohorts were meta-analyzed, the magnitude of asso-
ciation was similar and significant (OR per minor allele, 0.93;
95% CI, 0.89-0.97; P = 7.4 × 10−4), and there remained no
heterogeneity (I2 = 0%).
The rs174547 variant demonstrated a consistent associa-
tion with AVC in the CHARGE consortium (OR per minor al-
lele, 0.91; 95% CI, 0.83-0.99; P = .03). Results accessed from
PhenoScanner (eTable 9 in the Supplement) indicated that this
variant was also associated with other biochemical pheno-
types, including fatty acid and lipid measures, but only 1 dis-
ease entity, asthma, which is characterized by eicosanoid-
mediated inflammation. In the CARDIoGRAMplusC4D
consortium, there was a nominally significant association with
coronary artery disease (OR per minor allele, 0.98; 95% CI,
0.96-1.00; P = .03).
Associations of Fatty Acid Levels With AS and AVC
Due to the role of the FADS1/2 locus in ω-6 and ω-3 fatty acid
biosynthesis (Figure 3), we examined the association of ω-6
and ω-3 fatty acids as well as fatty acid ratios reflecting ω-6 and
ω-3 desaturation activity with AVC in the FOS and MESA co-
horts (Table 1 and eTable 10 in the Supplement). Higher lev-
els of arachidonic acid and a higher ratio of arachidonic acid
to linoleic acid, reflecting increased conversion of linoleic acid
to arachidonic acid, were associated with increased odds for
AVC, adjusted for age and sex (combined OR per SD of the natu-
ral logarithm of arachidonic acid levels, 1.12 [95% CI, 1.03-
1.22; P = .01]; combined OR per SD of the natural logarithm of
the ratio, 1.19 [95% CI, 1.09-1.30; P = 6.6 × 10−5]). These asso-
ciations were materially unchanged after adjustment for low-
density lipoprotein cholesterol level, systolic blood pressure,
smoking, and diabetes (Table 1). Neither eicosapentaenoic acid
nor the ratio of eicosapentaenoic acid to α-linolenic acid, re-
flecting increased conversion of α-linolenic acid to eicosapen-
taenoic acid, were associated with AVC. We did not observe
interactions between dietary linoleic acid and rs174547 for their
associations with incident AS or prevalent AVC (eTables 11 and
12 in the Supplement).
Mendelian Randomization of Arachidonic Acid Level
and FADS1 Expression With AS and AVC
To evaluate potential causality of ω-6 fatty acids in AS and AVC,
we used mendelian randomization to estimate the associa-
tions between a plasma arachidonic acid genetic risk score and
AS and AVC separately. Genetically elevated arachidonic acid
level was associated with a higher prevalence of AS and AVC,
with a 5–percentage point increase of arachidonic acid level
among total fatty acids corresponding to an 8% increase in the
odds for AS (OR, 1.08; 95% CI, 1.04-1.13; P = 4.1 × 10−4) and a
23% increase in the odds for AVC (OR, 1.23; 95% CI, 1.01-1.49;
Figure 3. Roles of FADS1 and FADS2 in the Conversion of 18-Carbon ω-6





















FADS1 and FADS2 perform the desaturation steps in the conversion of
18-carbon ω-6 and ω-3 fatty acids to arachidonic and eicosapentaenoic acids.
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For rs174547, C and T are the minor
and major alleles, respectively. The
sizes of the dark blue squares reflect
the weight of the cohorts in the
fixed-effects meta-analysis.
BioVU indicates Vanderbilt DNA
Biobank; EPIC-Norfolk, European
Prospective Investigation of Cancer
and Nutrition–Norfolk; GERA, Genetic
Epidemiology on Adult Health and
Aging; MDCS, Malmö Diet and Cancer
Study; NA, not applicable; OR, odds
ratio; PMBB, Penn Medicine BioBank;
and QUEBEC-CAVS, Quebec City
Case-Control Calcific Aortic Valve
Stenosis.
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P = .04). In sensitivity analyses excluding the rs174547 vari-
ant or accounting for the effects of the genetic risk score
through mechanisms other than arachidonic acid (ie, genetic
pleiotropy), we observed attenuation under some conditions
(Table 2), although the intercept in the Egger regressions was
not significant.
Mendelian randomization analysis also indicated that
genetically elevated FADS1 expression in the liver conferred
increased odds of AS (OR per unit increase of normalized ex-
pression, 1.31; 95% CI, 1.17-1.48; P = 7.4 × 10−6) and AVC (OR
per unit increase of normalized expression, 1.25; 95% CI, 1.02-
1.52; P = .03). Sensitivity analyses supported a potential causal
association of elevated FADS1 expression with AS and AVC, with
no evidence of directional pleiotropy (eTable 13 in the Supple-
ment). No significant FADS2 liver expression quantitative trait
loci were available.
Discussion
We conducted a GWAS for AS in the GERA cohort, with one of
the largest collections of cases of AS to date. The FADS1/2 vari-
ant rs174547 demonstrated association with prevalent AS, with
each copy of the minor allele conferring more than 10% lower
odds of the disease. In individuals homozygous for the minor
allele, we observed a 26% reduction in the odds of AS. The as-
sociation persisted after adjustments for LPA rs10455872, car-
diovascular risk factors, or population stratification. When the
discovery and 7 replication cohorts consisting of 312 118 indi-
viduals (9395 cases of AS) were combined, rs174547 reached
genome-wide significance. The association also persisted in
a sensitivity analysis excluding the discovery cohort, support-
ing a robust association with AS. The rs174547 variant was also
associated with prevalent AVC in the CHARGE consortium, pro-
viding additional evidence for a role in early valvular calcifi-
cation. Because the FADS1/2 locus is a key regulator of poly-
unsaturated fatty acid biosynthesis,14 we assessed the
association of several ω-6 and ω-3 fatty acid levels with AVC.
Increased production of the ω-6 arachidonic acid, but not the
ω-3 eicosapentaenoic acid, was associated with AVC, with
highly consistent results in 2 cohorts. We further observed that
genetically elevated FADS1 expression in the liver was asso-
ciated with increased odds of AS and AVC. Additional mende-
lian randomization analyses provided evidence of a poten-
tially causal association between plasma arachidonic acid, the
product of the ω-6 pathway, and both AS and AVC, although
we were unable to entirely exclude the possibility of pleiot-
ropy. Therefore, our results indicate that FADS1/2 variation is
a key determinant of valve calcification, demonstrate that
plasma ω-6 fatty acids are associated with valve calcium, and
suggest that increased ω-6 fatty acid biosynthesis may be a
causal pathway for AS.
Table 1. Associations of ω-6 and ω-3 Fatty Acids With Aortic Valve Calciuma
Fatty Acid Cohort
Adjusted for Age and Sex Fully Adjustedb
OR (95% CI) P Value OR (95% CI) P Value
ω-6
AA level
FOS 1.10 (0.97-1.25) .13 1.13 (0.98-1.29) .09
MESA 1.13 (1.01-1.27) .04 1.14 (1.01-1.29) .03
Combined 1.12 (1.03-1.22) .01 1.14 (1.04-1.24) 5.8 × 10−3
AA:LA
ratio
FOS 1.20 (1.06-1.37) 5.2 × 10−3 1.22 (1.06-1.39) 4.6 × 10−3
MESA 1.19 (1.06-1.34) 4.4 × 10−3 1.22 (1.08-1.38) 1.6 × 10−3
Combined 1.19 (1.09-1.30) 6.6 × 10−5 1.22 (1.11-1.34) 2.2 × 10−5
ω-3
EPA level
FOS 0.91 (0.80-1.04) .16 0.91 (0.80-1.04) .18
MESA 1.04 (0.92-1.16) .54 1.07 (0.95-1.21) .25
Combined 0.98 (0.90-1.07) .63 1.00 (0.91-1.09) .97
EPA:ALA
ratio
FOS 0.99 (0.87-1.12) .85 1.00 (0.88-1.15) .95
MESA 1.08 (0.96-1.22) .19 1.12 (0.99-1.26) .08
Combined 1.04 (0.95-1.13) .40 1.06 (0.97-1.16) .18
Abbreviations: AA, arachidonic acid;
ALA, α-linolenic acid;
EPA, eicosapentaenoic acid;
FOS, Framingham Offspring Study;
LA, linoleic acid; MESA, Multi-Ethnic
Study of Atherosclerosis; OR, odds
ratio.
a The ORs are calculated per SD of the
natural logarithm for AA and EPA
and per SD of the natural logarithm
of the ratio of the fatty acids for the
AA:LA and EPA:ALA ratios.
Estimates were combined via
fixed-effects meta-analysis
weighted by the inverse of their
variance.
b Adjusted for low-density lipoprotein
cholesterol level, systolic blood
pressure, current smoking, and
diabetes, in addition to age and sex.
Table 2. Genetic Associations of Arachidonic Acid
With Aortic Stenosis and Aortic Valve Calcium
Method
OR per 5–Percentage Point
Increase of AA Among
Total Fatty Acids (95% CI) P Value
Aortic Stenosis
Mendelian randomization 1.08 (1.04-1.13) 4.1 × 10−4
Excluding rs174547a 1.03 (0.99-1.08) .15
Inverse variance-weighted 1.08 (1.02-1.15) 8.9 × 10−3
Penalized weighted median 1.11 (1.03-1.20) 4.9 × 10−3
Egger extension to mendelian
randomization
1.02 (0.92-1.13) .72
Intercept for the Egger extension NA .15
Aortic Valve Calcium
Mendelian randomization 1.23 (1.01-1.49) .04
Excluding rs174547a 1.10 (0.82-1.49) .52
Inverse variance-weighted 1.23 (1.01-1.49) .04
Penalized weighted median 1.32 (1.04-1.68) .02
Egger extension to mendelian
randomization
1.08 (0.78-1.49) .63
Intercept for the Egger extension NA .32
Abbreviations: AA, arachidonic acid; NA, not applicable; OR, odds ratio.
a Genetic risk score is not associated with eicosapentaenoic acid.
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The rs174547 variant is located in an intron of FADS1, a
member of the FADS1/2/3 gene cluster. The function of
FADS3 is unknown, whereas FADS1 and FADS2 encode fatty
acid desaturases with key functions in the conversion of
dietary linoleic and α-linolenic acids into arachidonic and
eicosapentaenoic acids, respectively (Figure 3).14 Notably,
the rs174547 variant resides on a haplotype that extends
across FADS1 and part of FADS2, and the minor allele is asso-
ciated with decreased transcription of FADS1 and increased
transcription of FADS2 across most tissue types.15 The net
result is lower arachidonic acid levels and higher linoleic
acid levels,16,17 indicating that the conversion of dietary ω-6
fatty acids to longer-chain polyunsaturated fatty acids is less
active in minor allele carriers. The minor allele is also associ-
ated with lower levels of eicosapentaenoic acid and higher
levels of α-linolenic acid,18 mirroring the effects observed for
ω-6 long-chain fatty acid synthesis. However, the conversion
of α-linolenic acid to downstream products is inefficient,
and levels of long-chain ω-3 fatty acids are highly dependent
on diet.19 Arachidonic acid is a precursor for proinflamma-
tory prostaglandins and leukotrienes, whereas leukotrienes
and resolvins derived from eicosapentaenoic acid are
anti-inflammatory,20 and thus the enzymatic activities of
FADS1 and FADS2 proteins may have proinflammatory and
anti-inflammatory effects.
Although higher linoleic acid levels have been associated
with reduced risk of all-cause mortality and myocardial
infarction,21 many prior studies have not evaluated the con-
tribution of the ratio of arachidonic to linoleic acid (or
FADS1/2 genotypes), thereby overlooking interindividual
variation in the production of arachidonic acid. A ratio of
higher arachidonic acid to linoleic acid has been associated
with cardiovascular and all-cause mortality after adjustment
for risk factors,22 which suggests that FADS1 and FADS2 pro-
tein activity may independently contribute to cardiovascular
outcomes.
Several lines of evidence point to ω-6 fatty acids as pos-
sible causal mediators for AS. We found that a higher ratio of
arachidonic acid to linoleic acid (reflecting ω-6 desatura-
tion), but not the ratio of eicosapentaenoic acid to α-linolenic
acid (reflecting ω-3 desaturation), was associated with AVC.
This finding is consistent with our mendelian randomization
findings, which demonstrate that genetically elevated FADS1
expression, as well as arachidonic acid levels, were associ-
ated with AS and AVC, providing evidence of a causal link. A
greater conversion of linoleic acid to arachidonic acid may be
associated with a local proinflammatory state via increased
leukotrienes.23,24 Increased inflammation has been demon-
strated among patients with AS, as denoted by overexpres-
sion of interleukin-625 and interleukin-1β26 at the valve. In-
deed, local levels of leukotrienes B4 and C4, downstream
metabolites of arachidonic acid, are associated with the ex-
tent of valve calcification27 and aortic valve area,25 providing
a mechanistic link between production of arachidonic acid and
valve calcification and AS. Higher levels of arachidonic acid
in phospholipids, observed in explanted stenotic aortic
valves,28 may also increase their susceptibility to oxidation and
promote local inflammation and subsequent calcification.
Linking variation at the FADS1/2 locus to AS is compli-
cated by the multitude of identified biomarker associations,
which are all likely secondary to polyunsaturated fatty acid bio-
synthesis. The association of rs174547 with AS in the GERA co-
hort persisted when adjusted for dyslipidemia, hyperten-
sion, smoking, and diabetes. In the FOS and MESA cohorts, the
association between AVC and greater conversion of linoleic acid
to arachidonic acid also remained after adjustment for low-
density lipoprotein cholesterol level, systolic blood pressure,
smoking, and diabetes. Thus, the associations of rs174547 and
increased arachidonic acid with aortic valve outcomes are likely
to be independent of the effects of rs174547 on these risk fac-
tors. Our mendelian randomization of FADS1 expression fur-
ther demonstrates the key role of FADS1 and implicates fatty
acid desaturation in valve calcification. Finally, mendelian ran-
domization analyses for arachidonic acid were robust to plei-
otropy under certain assumptions such as penalized weighted
median, which allows for as many as 50% of the variants in
the genetic risk score to be pleiotropic. Because the intercept
did not differ significantly from zero in our Egger regression
for AS or AVC, no strong evidence of alternate pleiotropic path-
ways was observed. Together the present findings link FADS1/2
activity with AS and identify arachidonic acid as having a likely
causal association with disease. Further investigation will be
needed to delineate the downstream processes that link the
FADS1 and FADS2 locus and arachidonic acid to aortic valve
abnormalities.
Our results point to the FADS1/2 locus and ω-6 fatty acid
biosynthesis as potential therapeutic targets. Direct therapeu-
tic alteration of FADS1/2 expression, to mimic the observed ge-
netic effects and reduce fatty acid desaturation, may repre-
sent a therapeutic strategy for AS, which is supported by the
results of our mendelian randomization of FADS1 expression.
Alternatively, we speculate that the role of FADS1/2 in the con-
version of linoleic acid to arachidonic acid raises the possibil-
ity of dietary modification as a preventive strategy for AS. Both
approaches warrant further study as possible treatments
for AS.
Strengths and Limitations
Our discovery GWAS was performed in the GERA cohort with
one of the largest collections of cases with AS assembled to
date. Data from several large-scale cohorts provided robust rep-
lication for this novel association and extended it to relevant
fatty acid measures. Nonetheless, we note several limita-
tions. First, not all participants underwent echocardiogra-
phy, the criterion standard for diagnosing AS. We relied on a
heterogeneous definition of AS across cohorts that may not
have captured all cases, but misclassification of undiagnosed
AS cases as controls is likely to bias our results toward the null,
as is heterogeneity in our definition of controls. Our use of di-
agnosis and procedure codes to define AS also precludes an
assessment of disease severity. However, our case-finding
approach permits the study of AS in large cohorts without echo-
cardiographic data, has previously led to the discovery and
robust replication of the LPA locus (including in many of the
cohorts in the present study2,4,5,9,10), and has a positive pre-
dictive value exceeding 90%.2 We also observed no heteroge-
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neity in our meta-analysis of rs174547, suggesting the various
definitions for AS are concordant. Second, some mendelian ran-
domization sensitivity analyses lacked statistical power, in-
cluding Egger regression, which is a known limitation of this
approach. Third, we restricted our GWAS to participants with
self-reported European ancestry, because the number of non-
Europeans was low and the frequency of FADS1/2 variants var-
ies markedly across races/ethnicities.29 Fourth, although all
measured fatty acids were derived from blood, the measure-
ments were taken in red blood cells in the FOS cohort and in
plasma in the MESA cohort, and associations with AVC in both
cohorts were cross-sectional. However, results were highly con-
sistent across the 2 cohorts despite the different approaches.
Fifth, we focused on the FADS1/2 genes as likely candidates
in the locus and provide evidence in favor of this pathway. We
acknowledge that other genes nearby could also play a role,
but these are unlikely candidates based on their known biol-
ogy. In addition, although we observe modest reductions in
the odds of AS among participants with 1 or 2 copies of the mi-
nor allele, this reflects the natural genetic variation at a locus
with important biological function; targeting this locus by phar-
macological means could achieve larger reductions in the
odds of AS.
Conclusions
We demonstrate that a common variant in the FADS1/2 locus
is associated with AS and AVC. Concordant findings from bio-
marker measurements and mendelian randomization link
increased ω-6 fatty acid biosynthesis to the development of
AS, which may represent a novel therapeutic target.
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